Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial.

ABSTRACT:

Background

Early thromboprophylaxis does not prevent hospital admissions and death among outpatients with symptomatic COVID-19. Its impact on long-term outcomes, including long COVID symptoms and performance status, is unknown.

Objectives

To assess the long-term effects of thromboprophylaxis given at the time of acute COVID-19 in outpatients.

Methods

The OVID (enoxaparin for outpatients with COVID-19) trial randomized outpatients older than 50 years with acute COVID-19 to receive either subcutaneous enoxaparin 40 mg once daily for 14 days or standard of care (no thromboprophylaxis). In this follow-up study, we assessed the 2-year outcomes, including all-cause hospitalization and death, cardiovascular events, long COVID symptoms, and functional limitations based on the

SUBMITTER: Fumagalli RM 

PROVIDER: S-EPMC11381852 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature